Vanessa
Yen

Obtained first victory for pharmaceutical client in an inter partes review proceeding in the Hatch-Waxman context, where the PTAB upheld all challenged claims on patents covering Oracea®, a multi-million dollar drug product

Obtained trial win for client Galderma in a multi-party Hatch Waxman litigation where its longest-running patent covering Oracea® was successfully upheld by the U.S. District Court of Delaware and by the Federal Circuit on appeal (per curium)

Obtained favorable non-institution decision from the PTAB on behalf of a pharmaceutical client Galderma for all three inter partes review petitions in the Hatch-Waxman context

Obtained favorable settlements on behalf of pharmaceutical client Galderma with multiple defendants seeking approval for generic versions of its Oracea® drug product

Served as litigation counsel for numerous pharmaceutical companies in defending their patents on multi-billion and multi-million dollar drug products, including:

Eisai Co., Ltd. in a Hatch-Waxman action involving Banzel® (rufinamide), an antiepileptic drug product

Sunovion Pharmaceuticals Inc. in a Hatch-Waxman action involving Brovana® (arformoterol), a chronic obstructive pulmonary disease drug product

Shire LLC and Supernus Pharmaceuticals, Inc. in a Hatch-Waxman action involving Intuniv® (extended-release guanfacine), a non-stimulant treatment for ADHD

Gilead Sciences in a Hatch-Waxman action involving Truvada® (emtricitabine and tenofovir disoproxil fumarate), an anti-HIV-1 drug product

Novartis Pharmaceuticals in a Hatch-Waxman action involving Trileptal® (oxcarbazepine), an anti-epileptic drug product for the treatment of partial seizures

UCB and Celltech Pharmaceuticals in a Hatch-Waxman action involving Metadate CD® (methylphenidate hydrochloride), an ADHD drug product